S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   84.97 (+2.37%)
AMD   118.69 (-0.65%)
T   15.09 (-4.55%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.31 (+1.57%)
DIS   91.00 (+2.72%)
AMC   4.55 (+0.00%)
PFE   38.53 (+1.34%)
PYPL   64.25 (+1.90%)
NFLX   404.09 (+0.24%)
S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   84.97 (+2.37%)
AMD   118.69 (-0.65%)
T   15.09 (-4.55%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.31 (+1.57%)
DIS   91.00 (+2.72%)
AMC   4.55 (+0.00%)
PFE   38.53 (+1.34%)
PYPL   64.25 (+1.90%)
NFLX   404.09 (+0.24%)
S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   84.97 (+2.37%)
AMD   118.69 (-0.65%)
T   15.09 (-4.55%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.31 (+1.57%)
DIS   91.00 (+2.72%)
AMC   4.55 (+0.00%)
PFE   38.53 (+1.34%)
PYPL   64.25 (+1.90%)
NFLX   404.09 (+0.24%)
S&P 500   4,284.37 (+1.50%)
DOW   33,750.34 (+2.08%)
QQQ   354.88 (+0.82%)
AAPL   180.74 (+0.36%)
MSFT   334.34 (+0.53%)
META   274.38 (+0.65%)
GOOGL   125.09 (+1.11%)
AMZN   124.65 (+1.53%)
TSLA   215.98 (+4.08%)
NVDA   394.06 (-0.92%)
NIO   7.71 (+2.25%)
BABA   84.97 (+2.37%)
AMD   118.69 (-0.65%)
T   15.09 (-4.55%)
F   12.44 (+2.73%)
MU   68.67 (-0.61%)
CGC   0.84 (+0.66%)
GE   106.31 (+1.57%)
DIS   91.00 (+2.72%)
AMC   4.55 (+0.00%)
PFE   38.53 (+1.34%)
PYPL   64.25 (+1.90%)
NFLX   404.09 (+0.24%)
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) News Today

$0.64
-0.01 (-2.15%)
(As of 12:58 PM ET)
Compare
Today's Range
$0.64
▼
$0.67
50-Day Range
$0.52
▼
$0.70
52-Week Range
$0.50
▼
$2.41
Volume
10,360 shs
Average Volume
64,140 shs
Market Capitalization
$8.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media
Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.



CYCC Media Mentions By Week

CYCC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYCC
News Sentiment
▼
0.00

0.49
▲
Average
Medical
News Sentiment

CYCC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYCC Articles
This Week
▼
1

0
▲
CYCC Articles
Average Week

SourceHeadline
MarketBeat logoCyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com
americanbankingnews.com - June 2 at 4:48 AM
MarketBeat logoCyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.com
americanbankingnews.com - May 26 at 3:58 AM
msn.com logoOppenheimer Maintains Cyclacel Pharmaceuticals (CYCC) Outperform Recommendation
msn.com - May 26 at 3:44 AM
MarketBeat logoHead-To-Head Survey: Cyclacel Pharmaceuticals (NASDAQ:CYCC) versus Aldeyra Therapeutics (NASDAQ:ALDX)
americanbankingnews.com - May 20 at 2:46 AM
MarketBeat logoQ4 2023 Earnings Forecast for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issued By Brookline Capital Management
americanbankingnews.com - May 16 at 4:20 AM
MarketBeat logoCyclacel Pharmaceuticals (NASDAQ:CYCC) Research Coverage Started at StockNews.com
americanbankingnews.com - May 9 at 6:44 AM
finance.yahoo.com logoCyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
finance.yahoo.com - May 3 at 10:29 AM
MarketBeat logoCyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - May 1 at 5:48 AM
MarketBeat logoStockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)
americanbankingnews.com - April 23 at 5:46 AM
finance.yahoo.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript
finance.yahoo.com - March 8 at 11:56 PM
msn.com logoOppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know
msn.com - March 7 at 4:36 PM
msn.com logoA Preview Of Cyclacel Pharmaceuticals's Earnings
msn.com - March 3 at 3:29 PM
finance.yahoo.com logoCyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
finance.yahoo.com - January 30 at 10:58 AM
finance.yahoo.com logoCyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
finance.yahoo.com - December 15 at 12:47 PM
seekingalpha.com logoCyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 9 at 8:56 PM
msn.com logoEarnings Outlook For Cyclacel Pharmaceuticals
msn.com - November 8 at 4:16 PM
finance.yahoo.com logoHere's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release
finance.yahoo.com - November 7 at 1:43 PM
finance.yahoo.com logoCyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
finance.yahoo.com - October 26 at 11:37 AM
fool.com logoCyclacel Pharmaceuticals (NASDAQ: CYCC)
fool.com - October 14 at 5:10 PM
finance.yahoo.com logoCyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
finance.yahoo.com - October 13 at 9:50 AM
seekingalpha.com logoCyclacel stock rises 16% as net loss narrows, income grows
seekingalpha.com - August 11 at 5:56 PM
finance.yahoo.com logoCyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients
finance.yahoo.com - June 30 at 4:39 PM
finance.yahoo.com logoCyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
finance.yahoo.com - June 30 at 11:39 AM
seekingalpha.com logoCyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:13 PM
finance.yahoo.com logoCyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 4:13 PM
benzinga.com logoCyclacel Pharmaceuticals's Earnings Outlook
benzinga.com - May 10 at 1:51 PM
finance.yahoo.com logoCyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
finance.yahoo.com - May 4 at 10:09 AM
finance.yahoo.com logoCyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
finance.yahoo.com - April 19 at 12:05 PM
seekingalpha.com logoCyclacel Pharmaceuticals jumps on preclinical data for blood cancer treatment fadraciclib
seekingalpha.com - April 12 at 9:30 AM
finance.yahoo.com logoCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
finance.yahoo.com - March 28 at 5:53 PM
seekingalpha.com logoCyclacel Pharmaceuticals Q4 2021 Earnings Preview
seekingalpha.com - March 25 at 6:20 PM
finance.yahoo.com logoCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
finance.yahoo.com - March 22 at 7:53 AM
finance.yahoo.com logoCyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 9 at 7:49 AM
finance.yahoo.com logoCyclacel Pharmaceuticals, Inc. (CYCC)
finance.yahoo.com - February 26 at 8:18 PM
seekingalpha.com logoCyclacel Pharmaceuticals reveals plans for cancer drug programs for 2022
seekingalpha.com - January 6 at 1:16 PM
finance.yahoo.com logoCyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
finance.yahoo.com - January 6 at 8:13 AM
finance.yahoo.com logoCyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
finance.yahoo.com - December 23 at 8:01 AM
finance.yahoo.com logoVow ASA: Vow bags USD 5.2 million cruise retrofit contract
finance.yahoo.com - December 7 at 8:44 AM
finance.yahoo.com logoCyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update
finance.yahoo.com - October 29 at 8:02 AM
finance.yahoo.com logoCyclacel Pharmaceuticals Presenting at Three Conferences in September
finance.yahoo.com - September 8 at 8:14 AM
seekingalpha.com logoCyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 6:22 PM
nasdaq.com logoCyclacel Pharmaceuticals, Inc. Common Stock (CYCC)
nasdaq.com - August 10 at 10:21 PM
finance.yahoo.com logoCyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update
finance.yahoo.com - August 3 at 7:13 AM
nasdaq.com logoCyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock About To Put More Money In Your Pocket
nasdaq.com - July 13 at 2:37 PM
finance.yahoo.com logoCyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
finance.yahoo.com - July 7 at 7:59 AM
benzinga.com logoBenzinga Insights
benzinga.com - June 6 at 6:04 PM
seekingalpha.com logoChecking In On Cyclacel Pharmaceuticals
seekingalpha.com - April 7 at 5:46 PM
apnews.com logoCyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and ...
apnews.com - March 17 at 7:32 AM
finance.yahoo.com logoCyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 11 at 6:15 PM
marketbeat.com logoCyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded by Zacks Investment Research to Sell
marketbeat.com - February 26 at 7:47 PM
Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CYCC) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -